Important Laboratory CPT Codes for Clinical Laboratories

Clinical laboratory billing succeeds when codes reflect what was ordered, performed, and reported, no more, no less. While CPT coding may appear straightforward, laboratories today face increasing payer scrutiny around medical necessity, repeat testing, CLIA compliance, molecular diagnostics, and documentation accuracy. Each error is small in isolation but across hundreds of claims, these patterns compound into significant revenue loss and audit exposure.

In 2026, the stakes are higher. CMS updated the Clinical Laboratory Fee Schedule (CLFS) with rate adjustments affecting high-volume chemistry and molecular codes. Commercial payers are expanding prepayment review on genomic testing and molecular diagnostics. MAC contractors are issuing updated LCDs for vitamin D, HbA1c, and PSA frequency limits. And the MolDX program continues tightening coverage criteria for next-generation sequencing panels.

This guide walks through the most important laboratory CPT codes for clinical billing  organized by category, updated for 2026, and built around the five decision points that determine whether a lab claim pays or denies.

The Scope is limited to clinical laboratory services. Anatomic pathology and cytology are covered separately.

Five Lab Billing Decision Points That Determine Claim Accuracy

Before selecting any laboratory CPT code, five decisions determine whether the claim will pay, deny, or generate audit activity: 

1) Panel vs. individual analytes – Bill a panel only when all required components are performed and reported on the same date of service. A single missing component breaks the panel definition -bill individual analytes instead. Example: CPT 80053 (CMP) cannot be billed if any listed component is absent. 

2) Method alignment – Urinalysis codes depend on method and microscopy. 81002 (manual, no microscopy), 81003 (automated, no microscopy), 81001 (with microscopy). The code must match the method actually used such as billing 81002 when an automated analyzer was used is a systematic miscoding error that survives claim scrubbing but fails audit 

3) Medically necessary repeats – When repeating the same test on the same day to obtain a new clinical result (e.g., serial troponins or lactate), append modifier ‑91 to the repeated test and document the clinical reason. Do not use modifier ‑91 for QC repeats/instrumental issues.

4) CLIA and QW compliance – For CLIA‑waived tests, ensure the performing site holds an appropriate certificate and append QW when required. This is essential for rapid antigen tests (e.g., 87880, 87804, 87811) where missing QW produces automatic claim rejection at many payers. 

5) Molecular and PLA selection – If a proprietary or single‑laboratory assay exists, a corresponding PLA U‑code generally applies; use the PLA code instead of a generic 812xx–814xx molecular code. Review quarterly updates before submitting the molecular claims.

Practical scenarios

Scenario A -Broken panel definition – A basic metabolic panel (80048) is ordered. The ordering physician adds an analyte not included in the BMP definition. Billing 80048 will deny because the panel definition is not met. Use individual analytes when the panel definition is not met.  

Scenario B -UA code mismatch – A site transitions to automated urinalysis but continues to bill 81002. Align coding to 81003 (automated, no microscopy) or 81001 (with microscopy) depending on whether microscopy was performed. This systematic error survives claim scrubbing because payers don’t see the method  but it surfaces immediately in an audit.

Scenario C -Serial cardiac enzymes – Troponin (84484) at 0h, 1h, 3h for ACS rule‑out. Append modifier 91 to the 1h and 3h repeat tests and document protocol‑based necessity in the medical record. Without modifier 91, payers reject the repeat tests as duplicate billing. 

Building scenario-specific coding guidance into your LIS or EHR charge capture workflow prevents these errors at the source. 

2026 Laboratory Billing Updates:  CLFS, PLA, and MAC Policy Changes

Laboratory billing is shaped by significant regulatory and coding changes. From CLFS rate adjustments to new PLA codes and MAC policy updates, labs must adapt quickly to avoid denials and revenue loss.

CLFS Rate Adjustments: What Labs Need to Know

CMS implemented Clinical Laboratory Fee Schedule (CLFS) rate changes effective January 1, 2026. High‑volume chemistry codes such as HbA1c (83036), TSH (84443), and lipid panels (80061) were adjusted under the PAMA methodology.

Action Step: Update fee schedule crosswalks before submitting claims to prevent underbilling.

PLA Code Quarterly Releases: Avoiding Denials

The AMA introduced new Proprietary Laboratory Analyses (PLA) U‑codes in Q1 and Q2 2026. Many molecular oncology assays now require PLA codes instead of generic 812xx codes.

Action Step: Review quarterly PLA updates against your test menu to ensure correct code assignment and avoid payer denials.

MolDX Coverage Policy Updates for NGS Panels

Palmetto GBA’s MolDX program updated technical assessment requirements for next‑generation sequencing (NGS) panels. Labs billing 81445, 81450, or 81455 without current MolDX approval are facing systematic denials.

Action Step: Confirm MolDX approval for all NGS panels before billing.

MAC LCD Changes Impacting Common Tests

Several MACs updated Local Coverage Determinations (LCDs) in 2025–2026, tightening coverage and frequency rules:

• Vitamin D (82306) → stricter coverage criteria
• PSA (84153) → updated frequency and diagnosis requirements
• HbA1c (83036) → clarified monitoring frequency documentation
• Cardiac biomarkers → new documentation requirements for non‑acute settings

Action Step: Align documentation with updated LCDs to avoid frequency‑based denials.

High‑utilization codes and usage notes

Panels

• 80048 Basic Metabolic Panel -bill only when all BMP components are performed on the same DOS with glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium. .
• 80053 Comprehensive Metabolic Panel. All 14 components required. Confirm panel integrity before billing where a single missing component converts to individual analyte billing. .
• 80061 Lipid Panel -observe frequency limits and confirm screening vs. diagnostic indications.
• 80076 Hepatic Function Panel -all listed analytes must be performed.

Chemistry / Endocrine

• 83036 Hemoglobin A1c -Most frequently billed endocrine code.Document necessity if testing occurs outside routine monitoring intervals  then  payer frequency limits apply. .
• 84443 TSH; 84439 Free T4; 84481 Free T3 -apply when clinically indicated. Document clinical indication clearly for each test ordered. 
• 82947 Glucose (quantitative), 82565 Creatinine, 82310 Calcium, 83735 Magnesium, 84100 Phosphorus, 82040 Albumin.
• 84460 ALT, 84450 AST, 84075 ALP, 82247 Bilirubin total (pair 82248 direct as appropriate).
• 83690 Lipase (preferred over 82150 amylase in many protocols), 83605 Lactate (consider modifier 91 for protocol‑driven same day repeats).
• 82306 Vitamin D, 82607 B12, 82728 Ferritin, 83540/83550 Iron/TIBC, 86140/86141 CRP/hs‑CRP, 84484 Troponin, 83880 BNP/NT‑proBNP per methodology.

Hematology / Coagulation

• 85025 CBC with automated differential; 85027 CBC without differential. Select based on whether the differential was performed and reported. 
• 85610 PT/INR; 85730 PTT; 85379 D‑dimer; 85384 Fibrinogen; 85732 Thrombin time.
• 85045 Reticulocyte count; 85652 ESR.

Urinalysis & Kidney

• 81002 / 81003 / 81001 -Urinalysis with microscopy (automated or manual). 81002 -Manual urinalysis, without microscopy. 81003 -Automated urinalysis, without microscopy. The most common laboratory billing error in urinalysis: billing 81002 when an automated analyzer was used. Match the code to the actual method and microscopy status documented in the LIS
• 82043  Urine microalbumin (quantitative). Pair with 82570 (urine creatinine) when calculating ACR per payer rules.
• 81025  Urine pregnancy test (visual color comparison).

Arterial/Venous Blood Gases

• 82803 – Blood gases (pH, pCO₂, pO₂ ± O₂ sat) -document clinical indication; consider modifier 91 when same-day repeats are protocol-driven and clinically necessary and should be documented in the record. 

Microbiology -Cultures & Rapid Antigen

• 87040 Blood culture (aerobic); 87086 Urine culture (quantitative); 87088 Additional isolate (urine).
• 87186 Antimicrobial susceptibility testing (microdilution/automated).
• 87880 Strep A antigen; 87804 Influenza antigen; 87811 SARS‑CoV‑2 antigen (ensure CLIA/QW compliance).

For all rapid antigen tests: confirm CLIA waiver certificate at performing site and append modifier QW when required. Missing QW produces automatic rejection at Medicare and most commercial payers. 

Infectious Disease -Serology & NAAT

• 86803 HCV antibody; 87340 HBsAg; 87389 HIV‑1/2 Ag/Ab (4th gen).
• 87635 SARS‑CoV‑2 NAAT (PCR); 87491 C. trachomatis NAAT; 87591 N. gonorrhoeae NAAT; 87493 C. difficile NAAT; 87624 High‑risk HPV DNA.

Bundling note: 87491 and 87591 are frequently ordered together. When billed on the same claim for the same specimen, confirm NCCI edit compliance and apply modifier 59 only when the tests are genuinely distinct by specimen source. Many payers bundle these into a combination code -confirm payer-specific policy before billing both separately. 

Method alignment, panel integrity, and CLIA/QW compliance are the three highest-frequency failure points in laboratory billing. Building code-level decision rules into your LIS charge master prevents these errors before claims are submitted. 

Toxicology

Toxicology billing is the most compliance-intensive category in clinical laboratory billing and the most searched. The fundamental distinction is between presumptive (screening) and definitive (confirmation) testing. 

Presumptive immunoassay codes (8030X, 8032X, 8035X families): Used for initial drug screening. Immunoassay-based detection that identifies the presence of a drug class rather than a specific drug. Billed per drug class analyzed. Documentation must support the clinical indication for the number of drug classes screened.

Definitive mass spectrometry codes (8036X–8037X families): Used for confirmation and quantification. Identifies specific drugs and metabolites by mass spectrometry. Billed per specimen based on the number of drug classes analyzed. Definitive testing requires clear documentation of why confirmation was clinically necessary beyond the presumptive result.

Critical billing rules for toxicology:

• Establish written reflex criteria specifying when presumptive results trigger definitive testing. Document the trigger in the result record.
• Apply frequency controls per payer LCD. Commercial payers and Medicare have specific limits on how often definitive testing can be billed.
• Do not bill definitive testing as a routine companion to every presumptive screen. Medical necessity for each definitive test must be independently supported.
• 2026 payer scrutiny: commercial payers are actively auditing toxicology claims where definitive testing rates appear disproportionate to the patient population or clinical indication.

Presumptive and definitive toxicology codes are among the most audited laboratory codes Written reflex protocols, frequency controls, and per-test medical necessity documentation are non-negotiable for audit-ready toxicology billing.

Molecular Pathology and Genetics CPT Codes Updates 

Category I molecular codes (812xx–814xx):

81445 -Solid organ neoplasm genomic sequence analysis panel, 5–50 genes. Requires MolDX approval for Medicare billing. Document tumor type, panel composition, and clinical rationale.

81450 -Hematolymphoid neoplasm genomic panel, 5–50 genes.

81455 -Expanded genomic panel, 51+ genes. Highest-scrutiny molecular code in 2026 -commercial payers requiring prior authorization and MolDX assessment before coverage.

Common Tier 1 single-gene codes: 81235 -EGFR. 81210 -BRAF. 81275/81276 -KRAS. Each requires documentation of the specific gene analyzed, tumor type, and clinical indication for targeted therapy selection.

PLA U-codes: For proprietary or single-laboratory assays, use the corresponding PLA U-code rather than a generic molecular code. PLA codes update quarterly -maintain a current PLA mapping table against your test menu and review at every quarterly AMA release.

Key changes:

• New PLA codes released in 2026 Q1 and Q2 cover several RNA fusion detection assays previously billed under unlisted codes.
• MolDX updated technical assessment requirements for ctDNA liquid biopsy panels.
• Prior authorization is now required by UnitedHealthcare and several BCBS plans for panels exceeding 50 genes.

Molecular pathology billing requires current MolDX approval, updated PLA code mapping, and prior authorization confirmation for large-panel NGS testing before specimens are processed.

Laboratory Billing Modifiers – Modifier 91, 90, and 59 Rules

Modifier	Purpose	When to Apply	Common Error
91	Repeat clinical diagnostic laboratory test with same test, same day, new result	Serial troponins, serial lactates, protocol-driven same-day repeats	Using for QC repeats or instrument failures not permitted
90	Reference laboratory	Your entity bills for a test performed by another lab when payer policy permits	Missing performing lab details on claim -produces rejection
59	Distinct procedural service	Tests are genuinely distinct by specimen, session, or indication with no more specific modifier exists	Overusing 59 to bypass bundling edits without clinical justification
QW	CLIA-waived test	Rapid antigen and other CLIA-waived point-of-care tests at waiver-certified sites	Missing QW with automatic rejection at Medicare and most commercial payers

ICD-10 Crosswalk for Common Laboratory Tests

CPT Code	Common Supporting ICD-10	Description
83036 (HbA1c)	E11.65 / E11.9	Type 2 diabetes with hyperglycemia / uncontrolled
84443 (TSH)	E03.9 / E05.90	Hypothyroidism / hyperthyroidism, unspecified
85025 (CBC)	D64.9 / R50.9	Confirm clinical indication either with Anemia or fever
80053 (CMP)	E87.6 / N18.3	Hypokalemia / CKD stage 3
80061 (Lipid panel)	E78.5 / Z13.220	Hyperlipidemia / screening for lipid disorder
82306 (Vitamin D)	E55.9 / M81.0	Vitamin D deficiency / osteoporosis
84484 (Troponin)	I21.9 / R07.9	Acute MI / chest pain
87635 (COVID-19 PCR)	U07.1 / Z20.828	COVID-19 confirmed / exposure
87491 (CT NAAT)	A56.00 / Z11.3	Chlamydial infection / screening
87340 (HBsAg)	B18.1 / Z11.59	Chronic HBV / screening

ICD-10 must align with the clinical indication in the order. A diagnosis-procedure mismatch is an independent denial trigger. Frequency limits are also diagnosis-dependent. Confirm that the submitted ICD-10 supports the billing frequency for tests like vitamin D and HbA1c. 

Documentation Standards That Reduce Laboratory Claim Denials 

• Order clarity: Panel vs. individual analytes, and a concise clinical reason.
• Specimen and method: Source and method (e.g., manual vs. automated UA; antigen vs. NAAT) consistent with the billed code.
• Panel integrity: Document that all components were performed when billing a panel code. 
• Repeat rationale: One line documenting protocol‑based or clinical need for modifier 91.
• CLIA/QW compliance: Confirm the site’s certificate and add QW as required.
• Frequency and necessity: Align with MAC/payer coverage policies for common tests.
• PLA Code mapping: Current PLA code used when applicable essay exists.

Common Laboratory Billing Errors 

Laboratory billing errors are often systematic, repeating across hundreds of claims before they are identified. To strengthen compliance and reduce denials, labs should focus on the following high‑risk areas:

• Panel billing errors → Panels such as 80048 or 80053 must only be billed when all components are performed. Confirm completeness before submitting the panel code.
• Urinalysis method mismatch → Codes 81001, 81002, and 81003 must align with the LIS‑documented method at charge capture.
• Missing modifier 91 → For protocol‑driven repeats (e.g., chemistry or cardiac markers), build modifier 91 triggers into LIS workflows.
• CLIA‑waived QW omission → Rapid tests such as 87880, 87804, and 87811 require the QW modifier. Make QW a mandatory field in POCT charge capture.
• PLA code mapping errors → Avoid billing generic molecular codes (812xx–814xx) when a PLA code exists. Maintain a current PLA mapping table and review quarterly.
• Panel unbundling → Do not bill panel codes and individual components separately on the same date of service. Audit claims for duplication.
• Modifier 90 misuse → Reference lab claims require performing lab NPI and CLIA details at claim generation.
• Definitive drug testing errors → Codes 8036X–8037X require reflex criteria documentation to establish medical necessity.

Most laboratory billing errors stem from system design gaps rather than isolated mistakes. Building code‑specific decision rules into LIS or EHR charge capture is far more effective than relying on post‑submission audits. Proactive prevention ensures compliance, reduces denials, and protects laboratory revenue

Staying Current with Minimal Effort

Preventing common laboratory billing denials doesn’t always require complex interventions. A few consistent, low‑effort practices can keep your coding and compliance workflows aligned with payer expectations:

• Review CLFS quarterly → Check for rate changes, QW modifier updates, and new code mappings.
• Monitor MAC and payer bulletins → Stay ahead of LCD/LCA updates that affect frequency limits and diagnosis requirements.
• Update PLA mappings quarterly → Incorporate new U‑codes as they are released to avoid denials tied to outdated generic codes.
• Share internal “what changed” notes → Brief updates help clinicians, coders, and billing staff stay aligned without heavy training sessions.

By embedding these lightweight routines into your workflow, labs can stay compliant, reduce denials, and protect revenue without adding unnecessary administrative burden.

FAQs

1. What is Modifier 91 in laboratory billing?

Modifier -91 is used when the same laboratory test is repeated on the same date of service to obtain a new clinical result. It should not be used for quality control, calibration, or instrument troubleshooting.

2. When should Modifier 90 be used?

Modifier -90 applies when a laboratory bills for a test performed by an outside reference laboratory, provided payer policy allows this billing arrangement.

3. What laboratory tests require the QW modifier?

Many CLIA-waived tests require the QW modifier, including rapid antigen tests such as CPT 87880, 87804, and 87811. Requirements vary by payer and test classification.

4. Can laboratory panels and individual analytes be billed together?

Generally, panel components should not be billed separately when the full panel criteria are met. Exceptions may apply when a specific analyte is repeated for medically necessary reasons.

5. How should repeat troponin testing be billed?

When clinically necessary repeat troponin testing occurs on the same day, Modifier -91 may be reported on subsequent tests, supported by protocol-based documentation and medical necessity.

6. When should a PLA code be used instead of a molecular pathology CPT code?

If a proprietary laboratory analysis (PLA) code exists for a specific assay, it generally replaces generic molecular pathology CPT coding. Laboratories should review quarterly CPT updates to maintain compliance.